The latest report by IMARC Group, titled “Viral Inactivation Market Report by Product (Reagents and Kits, Systems, Services), Application (Vaccines and Therapeutics, Stem Cell Products, Blood and Blood Products, Tissue and Tissue Products, Cellular and Gene Therapy), End Use (Pharmaceutical and Biotechnology Companies, CROs, Academic and Research Institutes, and Others), and Region 2025-2033,” finds that the global viral inactivation market size reached USD 691.7 Million in 2024. Viral inactivation is the primary step designed to enhance the safety of biotherapeutic products. Biotherapeutic products contain viruses that can become contaminated during the production process. They can invade cells, wherein they proliferate and result in various diseases. Consequently, viral inactivation is widely used to inhibit coat proteins and degrade nucleic acid within the virus. Today, it is available in different variants according to the characteristics of the virus and the type of biotherapeutic product. As a result, virus inactivation methods are gaining traction across the globe.
Global Viral Inactivation Market Trends:
The market is primarily driven by rising concerns about the transmission of blood-borne viruses through plasma-derived medicinal products. In addition, the implementation of stringent regulatory standards for developing biotherapeutic products is escalating the demand for viral inactivation to ensure the quality, safety, and efficacy of these products. Besides this, improved viral inactivation technologies and products are being employed in the food and beverage (F&B) industry to control the transmission of enteric viruses and ensure the safety of products. This, coupled with the development of new physical methods like supercritical fluids, pulsed electric fields, and gas plasma, is positively influencing the market growth. Looking forward, IMARC Group expects the market to reach USD 1,479.7 Million by 2033, exhibiting a growth rate (CAGR) of 8.38% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Million USD |
Segment Coverage | Product, Application, End Use, Region |
Region Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Charles River Laboratories, Merck KGaA, Parker Hannifin Corp, Rad Source Technologies, Sartorius AG, SGS SA, Terumo Corporation, Texcell, Vironova AB and WuXi AppTec |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us:
IMARC Group
30 N Gould St, Ste
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800